The present research is focused on spontaneous reports of ADRs related to T-DM1 and T-DXd filed in EV, undertaking a comprehensive context analysis in comparison to the other approved ADCs, T itself, other drugs prescribed for HER2-positive breast cancer, and to each other. Here, ERBB2 is linked to breast cancer.